Dr Reddy's Laboratories Revenue 2010-2024 | RDY

Dr Reddy's Laboratories annual/quarterly revenue history and growth rate from 2010 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Dr Reddy's Laboratories revenue for the quarter ending June 30, 2024 was $0.921B, a 12.18% increase year-over-year.
  • Dr Reddy's Laboratories revenue for the twelve months ending June 30, 2024 was $3.450B, a 9.42% increase year-over-year.
  • Dr Reddy's Laboratories annual revenue for 2024 was $3.35B, a 11.97% increase from 2023.
  • Dr Reddy's Laboratories annual revenue for 2023 was $2.992B, a 5.87% increase from 2022.
  • Dr Reddy's Laboratories annual revenue for 2022 was $2.826B, a 8.94% increase from 2021.
Dr Reddy's Laboratories Annual Revenue
(Millions of US $)
2024 $3,350
2023 $2,992
2022 $2,826
2021 $2,594
2020 $2,316
2019 $2,225
2018 $2,181
2017 $2,171
2016 $2,335
2015 $2,378
2014 $2,203
2013 $2,133
2012 $1,901
2011 $1,677
2010 $1,563
2009 $
Dr Reddy's Laboratories Quarterly Revenue
(Millions of US $)
2024-06-30 $921
2024-03-31 $835
2023-12-31 $866
2023-09-30 $828
2023-06-30 $821
2023-03-31 $718
2022-12-31 $826
2022-09-30 $788
2022-06-30 $660
2022-03-31 $671
2021-12-31 $715
2021-09-30 $778
2021-06-30 $662
2021-03-31 $673
2020-12-31 $675
2020-09-30 $661
2020-06-30 $585
2020-03-31 $458
2019-12-31 $618
2019-09-30 $682
2019-06-30 $558
2019-03-31 $604
2018-12-31 $535
2018-09-30 $543
2018-06-30 $543
2018-03-31 $525
2017-12-31 $590
2017-09-30 $553
2017-06-30 $513
2017-03-31 $608
2016-12-31 $546
2016-09-30 $538
2016-06-30 $479
2016-03-31 $527
2015-12-31 $603
2015-09-30 $614
2015-06-30 $591
2015-03-31 $621
2014-12-31 $610
2014-09-30 $579
2014-06-30 $586
2014-03-31 $580
2013-12-31 $571
2013-09-30 $537
2013-06-30 $478
2013-03-31 $613
2012-12-31 $522
2012-09-30 $544
2012-06-30 $457
2012-03-31 $522
2011-12-31 $522
2011-09-30 $462
2011-06-30 $444
2011-03-31 $453
2010-12-31 $424
2010-09-30 $420
2010-06-30 $363
2010-03-31 $365
2009-12-31 $373
2009-09-30 $382
2009-06-30 $381
2009-03-31 $390
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $12.399B $3.350B
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00